Join AbbVie for their upcoming National Broadcast: New Evidence in First-Line AML and Exploring Outcomes with Fixed-Duration Treatment in CLL, taking place on Thursday, 11/12 and Tuesday, 11/17 across multiple time zones. These educational events are in support of oncologists and care teams.  You may tailor the program to your audience by selecting to have the data delivered by MDs or APPs.

Attendees will have the opportunity to learn directly from experts in AML and CLL. During this interactive presentation we will:

  • Recognize VENCLEXTA as a BCL-2 inhibitor for 1L AML, and 1L and R/R CLL
  • Review the phase 3 efficacy and safety outcomes of VENCLEXTA + azacitidine from the pivotal VIALE-A study for patients with 1L AML, ineligible for intensive induction chemotherapy due to age or comorbidities
  • Explore the efficacy and safety outcomes of VENCLEXTA’s chemo-free, fixed duration CLL regimens

Please see the attached invitation with details and registration can be made via the links on the attached invitation or via your AbbVie representative.

ABV APP National Broadcast -TZ

ABV National Broadcast-TZ

Read More
image-title

MISSION STATEMENT/PHILOPSOPHY:

To provide the most powerful team of cancer experts investing in the health of our patients by pursuing the most advanced and innovative treatment methods and providing unrelenting dedication to our patients. 

LOCATIONS:

Tulsa Oklahoma

Bartlesville Oklahoma

McAlester Oklahoma

PRACTICE DETAILS (how many providers, how many employees, etc):

10 Medical Oncologists

4 Gyn Oncologists

4 Rad. Oncologists

3 Dermatologists specializing in cancer

14 Mid-levels

2 Pharm. Ds

QUALIFICATIONS/CREDENTIALS (are you QOPI certified, etc.):

QOPI Certified

ACHC Certified Specialty/Oncology Pharmacy

INTRODUCTION TO PHARMACY SERVICES STAFF W/ BRIEF BIO:

Darrell Willyard Pharm. D.

Linda Purdom RN OCN

Shelly Striplin Pharmacy Tech

Orlando Franco Pharmacy Tech, MA

DISPENSING TYPE (RETAIL VS DISPENSARY):

Oklahoma Licensed Retail Pharmacy

SERVICES PROVIDED (BONE MARROW, RADIATION, CHEMO):

62 Chair infusion Suite (Tulsa) 14 Chairs (Bartlesville) 12 chairs (McAlester)

Radiation (Tulsa)

Dermatology (Mohs Surgery) Tulsa

WHY DID  YOU JOIN NCODA?

Terrific way to meet and share ideas with other people with similar jobs/goals.

HOW DID YOU HEAR ABOUT US?

Mike Reff called and spoke to me.

HOW CAN NCODA HELP YOU?

My favorite part is networking at meetings.

As a small pharmacy with only 1 retail pharmacist- I appreciate the PQI and Oral Chemo Drug information sheets.  These save me time and manpower in having the work performed for me.

HOW WOULD YOU LIKE TO BE MORE INVOLVED WITH NCODA?

I am open to helping in any way that I am needed.

WHAT ARE SOME CHALLENGES YOU FACE NOW OR WILL FACE IN THE FUTURE OF ONCOLOGY?

We are working hard to manage DIR fees and to stop the outflow of prescriptions to other Specialty Pharmacies.

 

Read More
image-title

ONCOLYTICS TODAY

Completes BPA Worldwide Initial Business Publication Audit

SHELTON, CT, 10/5/20 – Oncolytics Today has completed its BPA Worldwide business publication audit.

Glenn J. Hansen, BPA Worldwide President, praised Oncolytics Today for voluntarily opening its records to independent verification and documentation of its circulation data.

Hansen pointed out that the audit facilitates the buying and selling of advertising space. A BPA Worldwide report provides advertisers and agencies with assurance that what they choose to invest in does, in fact, reach target audiences for specific ads. The BPA Worldwide audit also helps media companies by documenting the quality of their audiences.

Copies of the initial BPA Worldwide audit report for Oncolytics Today are available from BPA Worldwide or the publisher.

Oncolytics Today will be issuing semi-annual Brand Reports.

BPA Worldwide conducts its circulation audits on an annual basis following accepted auditing procedures. In addition to verifying exact counts of recipients, BPA Worldwide also documents that they are qualified in the markets served by the publications.

View the full Press Release HERE.

Read More